Gouws Capital LLC Has $6.78 Million Stake in Stryker Co. (NYSE:SYK)

Gouws Capital LLC grew its position in Stryker Co. (NYSE:SYK) by 4.5% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 19,924 shares of the medical technology company’s stock after buying an additional 852 shares during the period. Stryker accounts for about 4.9% of Gouws Capital LLC’s portfolio, making the stock its 7th largest position. Gouws Capital LLC’s holdings in Stryker were worth $6,779,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of SYK. Mill Capital Management LLC increased its position in Stryker by 15.6% during the 2nd quarter. Mill Capital Management LLC now owns 4,819 shares of the medical technology company’s stock valued at $1,640,000 after buying an additional 649 shares in the last quarter. Essex Financial Services Inc. grew its stake in shares of Stryker by 12.3% during the second quarter. Essex Financial Services Inc. now owns 3,256 shares of the medical technology company’s stock worth $1,108,000 after acquiring an additional 356 shares during the last quarter. Turtle Creek Wealth Advisors LLC increased its holdings in shares of Stryker by 2,521.7% during the second quarter. Turtle Creek Wealth Advisors LLC now owns 15,966 shares of the medical technology company’s stock valued at $5,432,000 after acquiring an additional 15,357 shares in the last quarter. Aptus Capital Advisors LLC raised its position in shares of Stryker by 30.2% in the 2nd quarter. Aptus Capital Advisors LLC now owns 66,801 shares of the medical technology company’s stock valued at $22,729,000 after purchasing an additional 15,506 shares during the last quarter. Finally, CWS Financial Advisors LLC boosted its stake in Stryker by 4.3% in the 2nd quarter. CWS Financial Advisors LLC now owns 256,789 shares of the medical technology company’s stock worth $87,373,000 after purchasing an additional 10,693 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on SYK shares. Needham & Company LLC raised their price target on shares of Stryker from $392.00 to $393.00 and gave the stock a “buy” rating in a report on Thursday, August 1st. Truist Financial reduced their target price on Stryker from $364.00 to $345.00 and set a “hold” rating for the company in a research note on Thursday, August 1st. BTIG Research boosted their price target on Stryker from $360.00 to $374.00 and gave the company a “buy” rating in a research note on Wednesday. Evercore ISI reduced their price objective on Stryker from $370.00 to $365.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $386.00 target price on shares of Stryker in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average target price of $373.84.

Insider Activity at Stryker

In other Stryker news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now directly owns 9,069 shares in the company, valued at $3,219,495. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Stryker news, insider Viju Menon sold 600 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the completion of the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 190,000 shares of Stryker stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $323.46, for a total value of $61,457,400.00. Following the completion of the sale, the director now directly owns 3,316,608 shares in the company, valued at $1,072,790,023.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 210,600 shares of company stock valued at $68,330,400. 5.90% of the stock is owned by company insiders.

Stryker Stock Performance

SYK traded up $2.49 on Friday, reaching $360.42. The stock had a trading volume of 1,307,583 shares, compared to its average volume of 1,185,878. The business’s 50-day moving average price is $337.13 and its two-hundred day moving average price is $341.57. The company has a market cap of $137.35 billion, a P/E ratio of 41.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.89. Stryker Co. has a 12-month low of $249.98 and a 12-month high of $361.41. The company has a current ratio of 1.68, a quick ratio of 0.95 and a debt-to-equity ratio of 0.51.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, beating the consensus estimate of $2.79 by $0.02. The firm had revenue of $5.42 billion during the quarter, compared to analyst estimates of $5.40 billion. Stryker had a return on equity of 22.89% and a net margin of 16.12%. Stryker’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.54 EPS. Sell-side analysts forecast that Stryker Co. will post 12 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Stockholders of record on Monday, September 30th will be given a dividend of $0.80 per share. The ex-dividend date is Monday, September 30th. This represents a $3.20 dividend on an annualized basis and a dividend yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 36.53%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.